Search

Author/Creator Langford, Ailsa

1. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Issue 10276 (27th February 2021)

Authors:
Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew; Scott, Andrew M; Lee, Sze-Ting; Kwan, Edmond M; Az...
Journal:
Lancet
Issue:
Volume 397:Issue 10276(2021)
Page Start:
797
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Issue 9 (September 2020)

Authors:
Nowak, Anna K; Lesterhuis, W Joost; Kok, Peey-Sei; Brown, Chris; Hughes, Brett GM; Karikios, Deme J; John, Thomas; Kao, Steven C-H; Leslie, Connull; Cook, Alistair M; Pavlakis, Nick; Briscoe, Karen; O'Byrne, Kenneth J; Karapetis, Christos S; Lam, Wei-Sen; Langford, Ailsa; Yip, Sonia; Stockler, Ma...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 9(2020)
Page Start:
1213
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901). (6th July 2021)

Authors:
Emmett, Louise; Subramaniam, Shalini; Joshua, Anthony M.; Crumbaker, Megan; Martin, Andrew; Zhang, Alison Y.; Rana, Nisha; Langford, Ailsa; Mitchell, Jenna; Yip, Sonia; Francis, Roslyn; Hofman, Michael S.; Sandhu, Shahneen; Azad, Arun; Gedye, Craig; McJannett, Margaret; Stockler, Martin R.; Davis...
Journal:
BJU international
Issue:
Volume 128:Number 5(2021)
Page Start:
642
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Issue 11 (November 2022)

Authors:
Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M; Lee, Sze-Ting; Azad, Arun A; McJannett, Margaret M; Stockler, Martin R; Williams, Scott G; Davis, Ian D; Hofman, Michael S; Akhurst, Tim; Ali...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 11(2022)
Page Start:
1389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗